+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

CD38 expression in B-cell chronic lymphocytic leukemia: Association with clinical presentation and outcome in 155 patients

CD38 expression in B-cell chronic lymphocytic leukemia: Association with clinical presentation and outcome in 155 patients

Haematologica 87(10): 1021-1027, October

Background and Objectives: To investigate whether CD38 expression at diagnosis is an independent predictor of survival and assess its associations with other clinical parameters used in the staging of B-cell chronic lymphocytic leukemia (B-CLL). Design and Methods: CD38 expression was analyzed in 155 consecutive unselected patients newly diagnosed with B-CLL from January 1991 to July 1997. In all cases CD38 expression was evaluated at diagnosis and patients were classified into two groups: those with gtoreq30% were considered positive (CD38+) and those with <30% were considered negative (CD38-). Statistical differences between each group were analyzed using chi2 tests for categorical variables and Student's t-tests for continuous variables. Survival analysis was performed at the univariate level by the Kaplan Meier technique and at the multivariate level by Cox hazard models. Results: Thirty (19%) patients were CD38+. CD38+ was associated with atypical morphology (p=0.004), a diffuse bone marrow pattern (p=0.016), Rai stage gtoreq2 (p=0.009), high lactate dehydrogenase (p=0.02), high beta2 microglobulin (p=0.004), and higher lymphocyte count (p=0.02). Furthermore, CD38+ patients required treatment more frequently (p=0.006) and CLL-related mortality was significantly higher (p=0.012). When we divided the study group into patients with Rai 0-1 and Rai 2-4 stages, CD38 positivity was only significantly associated with mortality in the early stage patients (p=0.012 vs p=0.68). CD38 expression in the multivariate analysis lost its statistical significance. None of these results was modified when the CD38 cut-off was set at 20%. Interpretation and Conclusions: CD38 expression identifies a subgroup of B-CLL patients with aggressive clinical presentation and worse outcome. Its expression is probably associated with other prognostic factors, but the feasibility of determining this parameter makes it easily reproducible and adds prognostic information at diagnosis to aid prediction of the clinical course and outcome of B-CLL.

(PDF emailed within 1 workday: $29.90)

Accession: 010263047

Download citation: RISBibTeXText

Related references

CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. Haematologica 87(10): 1021-1027, 2002

CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leukemia & Lymphoma 42(1-2): 109-114, 2001

Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia. Cancer 97(8): 1914-1919, 2003

Association of CD38 expression and diagnostic immunophenotypic score in B cell chronic lymphocytic leukemia. Acta Haematologica 118(2): 126-128, 2007

Clinical presentation, progression, and outcome of patients with clonal B-cell counts of less than 5 × 10(9)/l, 5 to 10 × 10(9)/l, and more than 10 × 10(9)/l and chronic lymphocytic leukemia immunophenotype. American Journal of Clinical Pathology 143(1): 70-77, 2015

Gene Expression Profiling in CD38+ Versus CD38- B Cell Chronic Lymphocytic Leukemia. Blood 100(11): Abstract No 1480, November 16, 2002

Simultaneous expression of CD38 and its ligand CD31 by chronic lymphocytic leukemia B-cells: anecdotal observation or pathogenetic hypothesis for the clinical outcome?. Haematologica 88(3): 354-355, 2003

Immunophenotypic characterization of the leukemic B-cells from Iranian patients with chronic lymphocytic leukemia: association between CD38 expression and disease progression. Iranian Journal of Immunology 5(1): 25-35, 2008

Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 100(13): 4671-4675, 2002

CD38 Antigen Expression and Soluble P53 Levels Predict Outcome in B-Chronic Lymphocytic Leukemia. Blood 100(11): Abstract No 2322, November 16, 2002

Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 98(9): 2633-2639, 2001

Clinical presentation and outcome of Thai patients with chronic lymphocytic leukemia: retrospective analysis of 184 cases. Asian Pacific Journal of Allergy and Immunology 23(4): 197-203, 2006

Association of CD38 antigen expression with other prognostic parameters in early stages of chronic lymphocytic leukemia. Leukemia & Lymphoma 42(6): 1315-1321, 2002

CD38 expression does not change in B-cell chronic lymphocytic leukemia. Blood 100(8): 3052-3053, 2002

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99(3): 1023-1029, 2002